Anti-VEGF antibody therapies have been used in patients suffering from retinal degenerative diseases, but there are still unmet needs for alternative or combination therapy due to treatment failure or insufficient drug response and various side effects, such as anemia, myalgia, retinal pigment epithelial tears, cataract, elevated intraocular pressure, and intraocular inflammation [14]. Here, VEGFA is linked to anemia (phenotype).